Fundamental Analysis of CYTOKINETICS INC(NASDAQ:CYTK) stock

Fundamental Rating

Taking everything into account, CYTK scores 2 out of 10 in our fundamental rating. CYTK was compared to 609 industry peers in the Biotechnology industry. CYTK may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, CYTK is valued expensive at the moment.

Quickly go to:

1. Profitability

1.1 Basic Checks

CYTK had negative earnings in the past year.

In the past year CYTK has reported a negative cash flow from operations.

In the past 5 years CYTK always reported negative net income.

CYTK had negative operating cash flow in 4 of the past 5 years.

1.2 Ratios

CYTK has a Return On Assets of -71.12%. This is in the lower half of the industry: CYTK underperforms 68.67% of its industry peers.

		Industry Rank	Sector Rank
ROA	-71.12%
ROE	N/A
ROIC	N/A

ROA(3y)-29.26%

ROA(5y)-36.02%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CYTK so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

CYTK does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, CYTK has more shares outstanding

The number of shares outstanding for CYTK has been increased compared to 5 years ago.

Compared to 1 year ago, CYTK has a worse debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of -3.45, we must say that CYTK is in the distress zone and has some risk of bankruptcy.

The Altman-Z score of CYTK (-3.45) is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-3.45

ROIC/WACCN/A

WACC10.89%

2.3 Liquidity

CYTK has a Current Ratio of 7.23. This indicates that CYTK is financially healthy and has no problem in meeting its short term obligations.

CYTK has a Current ratio of 7.23. This is in the better half of the industry: CYTK outperforms 66.00% of its industry peers.

A Quick Ratio of 7.23 indicates that CYTK has no problem at all paying its short term obligations.

CYTK has a Quick ratio of 7.23. This is in the better half of the industry: CYTK outperforms 66.17% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	7.23
Quick Ratio	7.23

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for CYTK have decreased strongly by -76.36% in the last year.

CYTK shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -94.72%.

CYTK shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 47.83% yearly.

EPS 1Y (TTM)-76.36%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q11.18%

Revenue 1Y (TTM)-94.72%

Revenue growth 3Y52.07%

Revenue growth 5Y47.83%

Revenue growth Q2Q-84.92%

3.2 Future

Based on estimates for the next years, CYTK will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.23% on average per year.

CYTK is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 56.25% yearly.

EPS Next Y-18.44%

EPS Next 2Y-3.6%

EPS Next 3Y5.7%

EPS Next 5Y17.23%

Revenue Next Year-83.07%

Revenue Next 2Y-45.26%

Revenue Next 3Y25.8%

Revenue Next 5Y56.25%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CYTK. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CYTK. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-3.6%

EPS Next 3Y5.7%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for CYTK!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

CYTOKINETICS INC

NASDAQ:CYTK (12/8/2023, 7:00:01 PM)

After market: 34.1 0 (0%)

34.1

-0.76 (-2.18%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap3.34B

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-71.12%
ROE	N/A
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.01

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	7.23
Quick Ratio	7.23
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)-76.36%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y-18.44%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-94.72%

Revenue growth 3Y52.07%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

CYTOKINETICS INC (CYTK)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens